Cybrexa appoints Jaya Gautam as SVP of technical operations
US clinical-stage oncology biotech Cybrexa Therapeutics has appointed Jaya Gautam as senior vice president, technical operations.
Dr Gautam joins several other recent company-wide hires, all of whom have been tasked with advancing and scaling CBX-12 into Phase II clinical trials and providing strategic support for the additional pipeline assets, like CBX-15, as the company prepares for investigational new drug (IND) submission.
“We are pleased to have Jaya join us at a pivotal point in the clinical development of our lead therapeutic, CBX-12, as we prepare to enter Phase II clinical trials,” said Per Hellsund, president and chief executive of Cybrexa. “Jaya offers extensive experience in operations as well as peptide and small molecule manufacturing that strongly align with the needs of our evolving pipeline and our growing clinical and commercial objectives,” he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze